These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1761450)

  • 21. Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
    Med Lett Drugs Ther; 2014 Jun; 56(1445):51-2. PubMed ID: 24956309
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
    Ramsey BW; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Kravitz RM; Schidlow DV; Wilmott RW; Astley SJ; McBurnie MA
    N Engl J Med; 1993 Jun; 328(24):1740-6. PubMed ID: 8497284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive performance of Sawchuk-Zaske and Bayesian dosing methods for tobramycin.
    Rodvold KA; Blum RA
    J Clin Pharmacol; 1987; 27(5):419-24. PubMed ID: 3693587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
    Adeboyeku D; Jones AL; Hodson ME
    J Cyst Fibros; 2011 Jan; 10(1):25-30. PubMed ID: 20920848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of cefoperazone sodium vs methicillin, ticarcillin, and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis.
    Jewett CV; Ledbetter J; Lyrene RK; Brasfield DM; Tiller RE
    J Pediatr; 1985 Apr; 106(4):669-72. PubMed ID: 3845095
    [No Abstract]   [Full Text] [Related]  

  • 26. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Ryan G; Jahnke N; Remmington T
    Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Gappa M; Steinkamp G; Tümmler B; von der Hardt H
    Scand J Gastroenterol Suppl; 1988; 143():74-6. PubMed ID: 3164515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
    Glass S; Plant ND; Spencer DA
    J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis.
    Bosso JA; Black PG; Matsen JM
    Am J Med; 1987 Apr; 82(4A):180-4. PubMed ID: 3555033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Blumer JL; Saiman L; Konstan MW; Melnick D
    Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
    Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
    Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis.
    Parry MF; Neu HC
    J Infect Dis; 1976 Aug; 134 Suppl():S194-7. PubMed ID: 823276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
    Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of pseudomonas infections in cystic fibrosis using tobramycin.
    McCrae WM
    Scott Med J; 1976 Apr; 21(2):68-9. PubMed ID: 940997
    [No Abstract]   [Full Text] [Related]  

  • 37. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring.
    de Hoog M; Mouton JW; Schoemaker RC; Verduin CM; van den Anker JN
    Clin Pharmacol Ther; 2002 May; 71(5):349-58. PubMed ID: 12011820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease.
    Paporisz U; Posselt HG; Wönne R; Ristow W; Röser D; Knothe H; Bender SW
    Monogr Paediatr; 1979; 10():31-3. PubMed ID: 460275
    [No Abstract]   [Full Text] [Related]  

  • 39. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG; Gembitskaia TE
    Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.